Biofrontera (BFRA) Receives Daily Coverage Optimism Rating of 0.03

Press coverage about Biofrontera (NASDAQ:BFRA) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biofrontera earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8272779996009 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of brokerages recently issued reports on BFRA. Zacks Investment Research downgraded Biofrontera from a “hold” rating to a “sell” rating in a research note on Monday. ValuEngine upgraded Biofrontera from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Lake Street Capital assumed coverage on Biofrontera in a research note on Wednesday, April 25th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Benchmark assumed coverage on Biofrontera in a research note on Friday, March 9th. They issued a “buy” rating and a $19.00 price target for the company.

Biofrontera traded up $0.24, hitting $13.49, during midday trading on Thursday, Marketbeat Ratings reports. The company’s stock had a trading volume of 292 shares, compared to its average volume of 11,297. Biofrontera has a 12 month low of $11.25 and a 12 month high of $17.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 9.90 and a quick ratio of 9.03. The company has a market capitalization of $304.19 million and a price-to-earnings ratio of -14.99.

Biofrontera (NASDAQ:BFRA) last posted its quarterly earnings results on Monday, April 30th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $5.53 million during the quarter. Biofrontera had a negative return on equity of 148.20% and a negative net margin of 106.21%. sell-side analysts anticipate that Biofrontera will post -0.4 EPS for the current fiscal year.

Biofrontera Company Profile

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply